AEB071 + MEK162

Phase 1/2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveal Melanoma

Conditions

Uveal Melanoma

Trial Timeline

Aug 1, 2013 → May 1, 2015

NCT ID

NCT01801358

About AEB071 + MEK162

AEB071 + MEK162 is a phase 1/2 stage product being developed by Pfizer for Uveal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01801358. Target conditions include Uveal Melanoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01801358	Phase 1/2	Terminated	Aug 1, 2013	May 1, 2015	Uveal Melanoma

Competing Products

20 competing products in Uveal Melanoma

See all competitors

Product	Company	Stage	Hype Score
Pembrolizumab + Lenvatinib	Eisai	Phase 2	52
Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg	AstraZeneca	Phase 1	33
Pembrolizumab + Entinostat	Merck	Phase 2	52
Pembrolizumab + Olaparib	Merck	Phase 2	52
Pembrolizumab 25 MG/1 ML Intravenous Solution	Merck	Phase 2	52
AEB071	Novartis	Phase 1	33
LXS196 + LXS196 and HDM201	Novartis	Phase 1	33
DYP688	Novartis	Phase 1/2	41
RAD001 (Everolimus) and Pasireotide (SOM230) LAR	Novartis	Phase 2	52
ranibizumab + triamcinolone acetonide	Novartis	Phase 2/3	65
Crizotinib	Pfizer	Phase 2	51
Dacarbazine + Sunitinib	Pfizer	Phase 2	51
Binimetinib + Belinostat	Pfizer	Phase 2	51
Ipilimumab + Nivolumab	Bristol Myers Squibb	Phase 1	32
Nivolumab + Relatlimab	Bristol Myers Squibb	Phase 2	51
ipilimumab + Nivolumab	Bristol Myers Squibb	Phase 2	51
ZIV-Aflibercept + Cemiplimab	Sanofi	Phase 2	51
Ziv-Aflibercept	Regeneron Pharmaceuticals	Phase 2	51
XmAb®23104 + Yervoy® (ipilimumab)	ICON plc.	Phase 1	30
IDE196 + Binimetinib + Crizotinib	IDEAYA Biosciences	Phase 1/2	36

Other Products from Pfizer